Vivos Therapeutics Reports 70% Revenue Increase to $5.1 Million in Q1 2026

Vivos Therapeutics, Inc. reported a significant increase in revenue for the first quarter of 2026, with total revenue reaching approximately $5.1 million, a 70% increase from $3.0 million in the same period of 2025. This growth was primarily driven by a substantial rise in service revenue, particularly from sleep testing services, which contributed approximately $2.0 million. However, product revenue saw a decline, with appliance sales to VIPs decreasing by about $0.9 million, offset by a $0.5 million increase in tooth positioner sales. The company recorded a net loss of $7.7 million for the quarter, compared to a loss of $3.9 million in the prior year, reflecting ongoing operational challenges and increased expenses.

The company's operational strategy has shifted significantly following the acquisition of The Sleep Center of Nevada (SCN) in June 2025, which has allowed Vivos to pivot towards a medical provider-focused sales and marketing model. This acquisition has enabled Vivos to manage both diagnostic and consulting revenues, creating higher-margin revenue streams. As of March 31, 2026, Vivos had approximately 13.5 million shares outstanding, an increase from 9.3 million shares at the end of 2025, reflecting efforts to raise capital through equity financing.

In terms of operational metrics, Vivos reported a gross profit of $3.1 million for the first quarter of 2026, resulting in a gross margin of 60%, up from 50% in the previous year. However, general and administrative expenses surged to $9.0 million, primarily due to costs associated with SCN's operations and increased personnel expenses. The company’s total liabilities stood at approximately $26.3 million, with cash and cash equivalents at $2.1 million, raising concerns about its ability to fund operations without additional financing.

Looking ahead, Vivos is actively seeking to bolster its stockholders' equity to comply with Nasdaq listing requirements, having received a notice regarding its failure to meet the minimum stockholders' equity requirement of $2.5 million. The company plans to submit a compliance plan to Nasdaq by June 1, 2026, and is exploring further acquisitions and strategic alliances to enhance revenue growth. Despite the challenges, Vivos remains focused on leveraging its new business model and the SCN acquisition to achieve positive cash flow and operational sustainability in the future.